RecruitingPhase 3NCT07265232

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Studying Spinal Muscular Atrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Lantu Biopharma
Intervention
vesemnogene lantuparvovec(biological)
Enrollment
15 enrolled
Eligibility
All sexes
Timeline
20252030

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07265232 on ClinicalTrials.gov

Other trials for Spinal Muscular Atrophy

Additional recruiting or active studies for the same condition.

See all trials for Spinal Muscular Atrophy

← Back to all trials